Back

Real world prospective one year monocentric follow up study investigating novel lipid lowering agents class proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab

11 April 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Risk Factors and Prevention - Lipids Lipids EAPC Premium Access EuroPrevent 2019

About the speaker

Photo
Mr Madan Raj Poudel

University Clinic OWL, Bielefeld (Germany)

15 More presentations in this session

Presentation thumbnail
Verification of the dutch criteria for familial hypercholesterolemia among a contingent of patients in southern Bulgaria
Doctor L. Kitova (Plovdiv, BG)
Presentation thumbnail
Lipid control in very high cardiovascular risk patients: what is the trend?
Doctor S. Cardoso Torres (Porto, PT)
Abstract
Presentation thumbnail
Physician-related factors associated with adherence to national guidelines for dyslipidemia management in primary care
Professor N. Pogosova (Moscow, RU)
Abstract
Presentation thumbnail
Cardiovascular risk according to SCORE and lipoprotein (a) - Does the association exist in Saint Petersburg population?
Doctor E. Kolesova (Saint-Petersburg, RU)
Abstract
Presentation thumbnail
The role of lipoprotein a as a cardiovascular risk factor in primary prevention screening
Doctor J. Gilis-Januszewski (Bad Oeynhausen, DE)
Abstract

Access the full session

Session thumbnail
Poster Session 2 - Risk Factors and Prevention - Lipids

The Event

Event poster

EuroPrevent 2019

11 April - 13 April 2019
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
Lipidomics to fine-tune cardiovascular risk prediction and personalised treatment

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources